發(fā)布時(shí)間：2018-08-09 20:55

【摘要】：目的比較不同劑量阿托伐他汀鈣片治療缺血性腦血管病的臨床療效和安全性。方法將40例頸部血管存在斑塊患者隨機(jī)分為對(duì)照組20例和試驗(yàn)組20例。對(duì)照組予以阿托伐他汀鈣20 mg,qd,睡前口服;試驗(yàn)組予以阿托伐他汀鈣40 mg,qd,睡前口服。2組患者均治療6個(gè)月。比較2組患者的臨床療效、血脂、頸部血管斑塊水平,以及藥物不良反應(yīng)的發(fā)生情況。結(jié)果治療后6個(gè)月,試驗(yàn)組和對(duì)照組的總有效率為分別95.00%(19例/20例)和85.00%(17例/20例),差異有統(tǒng)計(jì)學(xué)意義(P0.05)。治療后3,6個(gè)月,試驗(yàn)組的總膽固醇(TC)、三酰甘油(TG)、低密度脂蛋白膽固醇(LDL-C)分別為(2.61±0.31),(1.32±0.23),(1.98±0.31)mmol·L~(-1)和(2.23±0.27),(1.06±0.21),(1.75±0.26)mmol·L~(-1);頸部血管斑塊的斑塊長(zhǎng)度、斑塊厚度和斑塊面積分別為(7.08±0.17)mm,(1.27±0.15)mm,(8.99±1.10)mm~2和(6.76±0.21)mm,(1.18±0.26)mm,(8.01±1.14)mm~2。對(duì)照組治療后的3,6個(gè)月的TC、TG、LDL-C分別為(3.67±0.47),(1.56±0.29),(2.63±0.27)mmol·L~(-1)和(3.54±0.41),(1.42±0.25),(2.37±0.31)mmol·L~(-1);頸部血管斑塊的斑塊長(zhǎng)度、斑塊厚度和斑塊面積分別為(7.87±0.23)mm,(1.83±0.14)mm,(14.40±3.62)mm~2和(7.21±0.35)mm,(1.34±0.31)mm,(9.66±1.25)mm~2。2組患者的上述指標(biāo)比較,差異均有統(tǒng)計(jì)學(xué)意義(均P0.05)。試驗(yàn)組出現(xiàn)腹脹1例次,對(duì)照組出現(xiàn)惡心1例次,2組患者的藥物不良反應(yīng)發(fā)生率均為5.00%,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論阿托伐他汀鈣40 mg治療缺血性腦血管病的臨床療效與阿托伐他汀鈣片20 mg相當(dāng),然而前者在降脂和逆轉(zhuǎn)頸部血管斑塊方面的優(yōu)勢(shì)更加明顯,且不增加藥物不良反應(yīng)的發(fā)生率。
[Abstract]:Objective to compare the clinical efficacy and safety of different doses of Atto vastatin calcium tablets in the treatment of ischemic cerebrovascular diseases. Methods 40 patients with plaque in cervical vessels were randomly divided into control group (n = 20) and experimental group (n = 20). The control group was given Atto vastatin calcium 20 mg / g QD before bedtime, and the experimental group was treated with Atto vastatin calcium 40 mg / g QD before bedtime for 6 months. The clinical efficacy, blood lipid, cervical vascular plaque level and adverse drug reactions were compared between the two groups. Results six months after treatment, the total effective rates of the experimental group and the control group were 95.00% (19 / 20) and 85.00% (17 / 20), respectively. The difference was statistically significant (P0.05). 娌葷枟鍚，

本文編號(hào)：2175287